Author

J. T. Plummer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

A. A. Hamid· 1 shared A. F. Vallejo· 1 shared A. G. Sowalsky· 1 shared A. M. Bergman· 1 shared A. Swarbrick· 1 shared A. T. Ku· 1 shared B. G. Falcon· 1 shared C. J. Sweeney· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Hamid

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

snPATHO-seq: unlocking the FFPE archives for single nucleus RNA profiling

A. F. Vallejo, K. Harvey, T. Wang, K. Wise, L. M. Butler, J. Polo, J. T. Plummer, A. Swarbrick, L. G. Martelotto

This paper introduces snPATHO-Seq, a method for high-quality single nucleus RNA sequencing from FFPE samples, showing improved sensitivity and accuracy compared to existing methods.

bioRxiv · Aug 23, 2022 · PreprintCancer Biology

Loss of tristetraprolin activates NF-κB induced phenotypic plasticity and primes transition to lethal prostate cancer

K. L. Morel, A. A. Hamid, B. G. Falcon, J. N. Singh, S. Linder, A. M. Bergman, H. G. van der Poel, I. Hofland, E. M. Bekers, S. Trostel, S. Wilkinson, A. T. Ku, D. L. Burkhart, M. Kim, J. Kim, , L. Ellis

This study shows that loss of ZFP36 promotes NF-κB activation and phenotypic plasticity in prostate cancer, leading to aggressive disease and castration resistance, which can be reversed by NF-κB inhibition.

bioRxiv · Aug 5, 2022 · PreprintCancer Biology